Braeburn and Camurus enter arbitration proceedings in England
Lund, Sweden — 15 June 2020 — Camurus AB (NASDAQ STO: CAMX) today announces that, following its issuance of a material breach notice on its US partner Braeburn Inc., Braeburn has initiated arbitration proceedings in England, under the parties’ license agreement. Camurus has served Braeburn a material breach notice under the license agreement between the parties questioning Braeburn’s performance in respect of its efforts, including to prepare for regulatory approval and commercialization of Brixadi™ for the treatment of opioid dependence in Canada and as a weekly extended release product